Related Experiment Video

Updated: Sep 30, 2026

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi
07:56

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Published on: August 18, 2010

[New drugs that prevent cytotoxicity of Shiga toxins]

Yasuhiro Natori1

  • 1Clinical Pharmacology, Research Institute, International Medical Center of Japan.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|June 25, 2002
PubMed

Insights

New drugs targeting Shiga toxin (Stx) aim to prevent severe complications like hemolytic uremic syndrome. These Stx-neutralizing agents show promise for future clinical use in managing E. coli infections.

Area of Science:

  • Microbiology
  • Toxicology
  • Pharmacology

Context:

  • Enterohemorrhagic E. coli produces Shiga toxin (Stx), a key virulence factor responsible for enterohemorrhagic colitis and potentially fatal hemolytic uremic syndrome (HUS).
  • Current research focuses on developing novel therapeutic strategies to neutralize Stx and mitigate its severe systemic effects.
  • These strategies often involve mimicking the Gb3 receptor's trisaccharide structure to inhibit Stx activity.

Purpose:

  • To explore novel therapeutic agents targeting Shiga toxin (Stx) for the prevention of severe E. coli-associated complications.
  • To evaluate strategies for neutralizing Stx in both the gastrointestinal tract and systemic circulation.
  • To identify potential clinical candidates for preventing hemolytic uremic syndrome (HUS).

Summary:

  • Shiga toxin (Stx) from enterohemorrhagic E. coli causes severe illness, including HUS.
  • New drug candidates are being developed to bind Stx in the gut or neutralize it in the bloodstream.
  • These agents mimic the Stx receptor, Gb3, to inhibit toxin activity.

Impact:

  • Development of novel therapeutics to prevent life-threatening complications like HUS.
  • Potential for clinical application in managing infections caused by Shiga toxin-producing bacteria.
  • Advancement in understanding Stx-host interactions and designing targeted interventions.

Related Concept Videos

Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Bacterial Toxins01:12

Bacterial Toxins

Bacterial toxins are sophisticated virulence factors that enable pathogenic bacteria to interact with, invade, and damage host tissues. These toxins fall broadly into two types: protein exotoxins, which are secreted into the environment and target specific host receptors, and lipopolysaccharide endotoxins, which are structural components of the bacterial outer membrane released primarily during bacterial lysis or membrane shedding. Exotoxins generally act more selectively, binding to cell...
Bacterial Gastroenteritis01:18

Bacterial Gastroenteritis

Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid receptor...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...